Table: Astellas Pharma -6-MTH group results (IFRS)

Astellas Pharma

04/11/2026 06:30

04 Nov 2026 06:30:09

 Nov 04 (Reuters)-
Astellas Pharma
 CONSOLIDATED FINANCIAL HIGHLIGHTS

 (in billions of yen unless specified)

               6 months ended  6 months ended    Year to
              Sep 30, 2026    Sep 30, 2025   Mar 31, 2027
                 LATEST         YEAR-AGO        LATEST
                RESULTS         RESULTS        FORECAST
Sales          1.27 trln       1.03 trln      2.33 trln
              (+23.4 pct)     (+10.1 pct)     (+8.9 pct)
Operating        316.56          199.38         460.00
              (+58.8 pct)     (+112.8 pct)   (+20.2 pct)
Pretax           317.45          194.61         450.00
              (+63.1 pct)     (+118.6 pct)   (+19.5 pct)
Net              241.68          147.64         350.00
              (+63.7 pct)     (+100.8 pct)   (+20.1 pct)
EPS Basic      134.83 yen      82.44 yen      195.22 yen
EPS Diluted    134.47 yen      82.17 yen          --
Ann Div            --          78.00 yen      80.00 yen
-Q2 div        40.00 yen       39.00 yen          --
-Q4 div            --          39.00 yen      40.00 yen


 NOTE - Astellas Pharma.
(Figures are reported based on international accounting rules (IFRS).)

If there is no Q1 or Q3 dividend, Q2 will in most cases correspond to the first-half
dividend and Q4 to the second-half dividend announced before a new corporate law in
 2006 allowed companies to pay and report dividends on a quarterly basis.
  *Net - represents Net profit attributable to owners of the parent company.
 To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4503.T